Domača stranKVUE • NYSE
add
Kenvue Inc
Prejšnji trg. dan.
15,98 $
Dnevni razpon
15,95 $ - 16,45 $
Letni razpon
14,02 $ - 25,17 $
Tržna kapitalizacija
31,28 mrd. USD
Povprečni obseg
42,60 mio.
Razm. P/E
21,87
Dividendna donosnost
5,10 %
Primarna borza
NYSE
V novicah
Finančni podatki
Izkaz poslovnega izida
Prihodek
Čisti dohodek
| (USD) | jun. 2025info | Sprememba L/L |
|---|---|---|
Prihodek | 3,84 mrd. | −4,02 % |
Stroški poslovanja | 1,51 mrd. | −8,78 % |
Čisti dohodek | 420,00 mio. | 624,14 % |
Čista dobičkovnost prihodkov | 10,94 | 654,48 % |
Earnings per share | 0,29 | −9,38 % |
EBITDA | 902,00 mio. | 4,52 % |
Efektivna davčna stopnja | 28,57 % | — |
Bilanca stanja
Skupna sredstva
Skupne obveznosti
| (USD) | jun. 2025info | Sprememba L/L |
|---|---|---|
Denar. in kratkor. naložbe | 1,07 mrd. | 5,52 % |
Skupna sredstva | 27,13 mrd. | 2,61 % |
Skupne obveznosti | 16,40 mrd. | 0,84 % |
Celoten lastniški kapital | 10,73 mrd. | — |
Shares outstanding | 1,92 mrd. | — |
Razmerje P/B | 2,86 | — |
Donosnost sredstev | 7,12 % | — |
Donosnost kapitala | 9,90 % | — |
Denarni tok
Neto sprememba denarnih sredstev
| (USD) | jun. 2025info | Sprememba L/L |
|---|---|---|
Čisti dohodek | 420,00 mio. | 624,14 % |
Denar iz dejavnosti | 621,00 mio. | 41,14 % |
Denar iz naložb | −90,00 mio. | −5,88 % |
Denar iz financiranja | −548,00 mio. | −11,84 % |
Neto sprememba denarnih sredstev | 13,00 mio. | 109,22 % |
Prost denarni tok | 565,12 mio. | 27,86 % |
Vizitka
Kenvue Inc. is an American consumer health company. Formerly the Consumer Healthcare division of Johnson & Johnson, Kenvue owns well-known brands such as Aveeno, Band-Aid, Benadryl, Combantrin, Zyrtec, Johnson's, Listerine, Lactaid, Mylanta, Neutrogena, Trosyd, Calpol, Tylenol, and Visine. Kenvue is incorporated in Delaware and is headquartered in the Skillman section of Montgomery Township, New Jersey, with plans to relocate its global headquarters to Summit, New Jersey.
Johnson & Johnson announced in November 2021 that it would spin off its consumer health division as a separate company. The new company was named Kenvue in September 2022, and its initial public offering took place in May 2023, raising $3.8 billion in the largest U.S. IPO since 2021, with an initial valuation of about $41 billion. Johnson & Johnson initially retained more than 90% ownership before completing a full separation through a share exchange in July 2023. Kenvue was subsequently added to the S&P 500 Dividend Aristocrats index.
Kenvue employed about 22,200 people in 2022 and was first led by CEO Thibaut Mongon. Following Mongon’s termination in 2025, Kirk Perry was named interim CEO. Wikipedia
Datum ustanovitve
23. feb. 2022
Sedež organizacije
Spletno mesto
Zaposleni
22.000
